The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNA Vaccines Market Research Report 2025
Synopsis
RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
The global RNA Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of RNA Vaccines include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Vaccines.
Report Scope
The RNA Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Segment by Application
Infectious Disease
Cancer
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
The global RNA Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of RNA Vaccines include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Vaccines.
Report Scope
The RNA Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Segment by Application
Infectious Disease
Cancer
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 RNA Vaccines Market Overview
1.1 Product Overview and Scope of RNA Vaccines
1.2 RNA Vaccines Segment by Type
1.2.1 Global RNA Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Individualized Cancer Treatment MRNA Vaccine
1.2.3 Infectious Disease Treatment MRNA Vaccine
1.2.4 Infection Prevention MRNA Vaccine
1.3 RNA Vaccines Segment by Application
1.3.1 Global RNA Vaccines Market Value by Application: (2024-2030)
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Other
1.4 Global RNA Vaccines Market Size Estimates and Forecasts
1.4.1 Global RNA Vaccines Revenue 2019-2030
1.4.2 Global RNA Vaccines Sales 2019-2030
1.4.3 Global RNA Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 RNA Vaccines Market Competition by Manufacturers
2.1 Global RNA Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global RNA Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global RNA Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global RNA Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of RNA Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of RNA Vaccines, Product Type & Application
2.7 RNA Vaccines Market Competitive Situation and Trends
2.7.1 RNA Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest RNA Vaccines Players Market Share by Revenue
2.7.3 Global RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RNA Vaccines Retrospective Market Scenario by Region
3.1 Global RNA Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global RNA Vaccines Global RNA Vaccines Sales by Region: 2019-2030
3.2.1 Global RNA Vaccines Sales by Region: 2019-2024
3.2.2 Global RNA Vaccines Sales by Region: 2025-2030
3.3 Global RNA Vaccines Global RNA Vaccines Revenue by Region: 2019-2030
3.3.1 Global RNA Vaccines Revenue by Region: 2019-2024
3.3.2 Global RNA Vaccines Revenue by Region: 2025-2030
3.4 North America RNA Vaccines Market Facts & Figures by Country
3.4.1 North America RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America RNA Vaccines Sales by Country (2019-2030)
3.4.3 North America RNA Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe RNA Vaccines Market Facts & Figures by Country
3.5.1 Europe RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe RNA Vaccines Sales by Country (2019-2030)
3.5.3 Europe RNA Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific RNA Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific RNA Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific RNA Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America RNA Vaccines Market Facts & Figures by Country
3.7.1 Latin America RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America RNA Vaccines Sales by Country (2019-2030)
3.7.3 Latin America RNA Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa RNA Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa RNA Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa RNA Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global RNA Vaccines Sales by Type (2019-2030)
4.1.1 Global RNA Vaccines Sales by Type (2019-2024)
4.1.2 Global RNA Vaccines Sales by Type (2025-2030)
4.1.3 Global RNA Vaccines Sales Market Share by Type (2019-2030)
4.2 Global RNA Vaccines Revenue by Type (2019-2030)
4.2.1 Global RNA Vaccines Revenue by Type (2019-2024)
4.2.2 Global RNA Vaccines Revenue by Type (2025-2030)
4.2.3 Global RNA Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global RNA Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global RNA Vaccines Sales by Application (2019-2030)
5.1.1 Global RNA Vaccines Sales by Application (2019-2024)
5.1.2 Global RNA Vaccines Sales by Application (2025-2030)
5.1.3 Global RNA Vaccines Sales Market Share by Application (2019-2030)
5.2 Global RNA Vaccines Revenue by Application (2019-2030)
5.2.1 Global RNA Vaccines Revenue by Application (2019-2024)
5.2.2 Global RNA Vaccines Revenue by Application (2025-2030)
5.2.3 Global RNA Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global RNA Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Moderna Therapeutics
6.1.1 Moderna Therapeutics Corporation Information
6.1.2 Moderna Therapeutics Description and Business Overview
6.1.3 Moderna Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Moderna Therapeutics RNA Vaccines Product Portfolio
6.1.5 Moderna Therapeutics Recent Developments/Updates
6.2 CureVac
6.2.1 CureVac Corporation Information
6.2.2 CureVac Description and Business Overview
6.2.3 CureVac RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CureVac RNA Vaccines Product Portfolio
6.2.5 CureVac Recent Developments/Updates
6.3 Translate Bio
6.3.1 Translate Bio Corporation Information
6.3.2 Translate Bio Description and Business Overview
6.3.3 Translate Bio RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Translate Bio RNA Vaccines Product Portfolio
6.3.5 Translate Bio Recent Developments/Updates
6.4 BioNTech
6.4.1 BioNTech Corporation Information
6.4.2 BioNTech Description and Business Overview
6.4.3 BioNTech RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BioNTech RNA Vaccines Product Portfolio
6.4.5 BioNTech Recent Developments/Updates
6.5 Sangamo Therapeutics
6.5.1 Sangamo Therapeutics Corporation Information
6.5.2 Sangamo Therapeutics Description and Business Overview
6.5.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
6.5.5 Sangamo Therapeutics Recent Developments/Updates
6.6 Argos Therapeutics
6.6.1 Argos Therapeutics Corporation Information
6.6.2 Argos Therapeutics Description and Business Overview
6.6.3 Argos Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Argos Therapeutics RNA Vaccines Product Portfolio
6.6.5 Argos Therapeutics Recent Developments/Updates
6.7 In-Cell-Art
6.6.1 In-Cell-Art Corporation Information
6.6.2 In-Cell-Art Description and Business Overview
6.6.3 In-Cell-Art RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 In-Cell-Art RNA Vaccines Product Portfolio
6.7.5 In-Cell-Art Recent Developments/Updates
6.8 eTheRNA
6.8.1 eTheRNA Corporation Information
6.8.2 eTheRNA Description and Business Overview
6.8.3 eTheRNA RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 eTheRNA RNA Vaccines Product Portfolio
6.8.5 eTheRNA Recent Developments/Updates
6.9 Ethris
6.9.1 Ethris Corporation Information
6.9.2 Ethris Description and Business Overview
6.9.3 Ethris RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Ethris RNA Vaccines Product Portfolio
6.9.5 Ethris Recent Developments/Updates
6.10 Tiba Biotechnology
6.10.1 Tiba Biotechnology Corporation Information
6.10.2 Tiba Biotechnology Description and Business Overview
6.10.3 Tiba Biotechnology RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tiba Biotechnology RNA Vaccines Product Portfolio
6.10.5 Tiba Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 RNA Vaccines Industry Chain Analysis
7.2 RNA Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 RNA Vaccines Production Mode & Process
7.4 RNA Vaccines Sales and Marketing
7.4.1 RNA Vaccines Sales Channels
7.4.2 RNA Vaccines Distributors
7.5 RNA Vaccines Customers
8 RNA Vaccines Market Dynamics
8.1 RNA Vaccines Industry Trends
8.2 RNA Vaccines Market Drivers
8.3 RNA Vaccines Market Challenges
8.4 RNA Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
